Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 المشاهدات
• 07/02/23
0
0
تضمين
administrator
مشتركين
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
أظهر المزيد
تعليقات الفيسبوك
SORT BY-
أعلى تعليقات
-
أحدث تعليقات